LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025 /EINPresswire / -- What has been the historic growth trend in the abrysvo or arexvy global market and what is expected in the coming years?

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

This week we welcomed the federal government's announcement that a respiratory syncytial virus (RSV) vaccine for pregnant women would be included on ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

The Malinauskas Labor Government is partnering with the Albanese Federal Government to provide the infant component of the new National RSV Maternal ...

For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

Ritholtz Wealth Management decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 39.4% during the 4th ...